Preliminary Results Of Detailed Analysis

Vancouver, BC (July 6, 2006) - WEX Pharmaceuticals Inc. (the “Company”) is pleased to announce that the detailed analysis of the Phase IIb/III data collected during the double-blind, randomized, placebo controlled study of Tectin™ in inadequately controlled moderate to severe cancer pain is progressing.

The first phase of a detailed analysis using different parameters such as assessment of other pain scales, i.e. neuropathic pain scale, McGill Pain Questionnaire, and quality of life items (general activity, walking, mood, sleep, etc..) which were not examined by the Data Monitoring Committee is completed. Preliminary results are consistent with the results observed in the Phase IIa open label study. It should be noted, however, that these results are provisional and are still subject to review and validation.

Once the analysis is validated by an independent source the Company will determine the next steps in the clinical development of Tectin™ and provide additional information.

About WEX Pharmaceuticals Inc.
WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company’s principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company’s Chinese subsidiary sells generic products manufactured at its facility in China.

Forward Looking Statements

This News Release contains forward-looking statements which may not be based on historical fact. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact Information

Don Evans

V.P. Corporate Communications

WEX Pharmaceuticals Inc.

Contact via E-mail